Surgical palliation in patients with pancreatic cancer

Abstract

We advocate for an aggressive strategy in the treatment of pancreatic cancer with surgical exploration and tumor resection whenever possible.

Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma

“…The morbidity rate related to the associated surgery was 8·4 per cent, in keeping with the literature regarding surgical palliation in pancreatic cancer18. The RFA‐related complications were comparable both in primary and in second‐line treatments.…”

Outcome of Distal Pancreatectomy for Pancreatic Adenocarcinoma

“…Although, several investigators, especially those from high-volume centers, have recently proposed resection as an effective modality for palliation with the declining mortality of pancreatic surgery [32], one must be cautious as pancreatic surgery is still associated with a high morbidity rate and the outcome of these patients are uniformly poor. Our experience with R2 resections confirms this dismal outcome whereby the median survival of these patients was only 8 months as opposed to 15 months for patients undergoing R1 or R0 resections.…”

“…Our experience with R2 resections confirms this dismal outcome whereby the median survival of these patients was only 8 months as opposed to 15 months for patients undergoing R1 or R0 resections. However, it is important to remember that the more aggressive the attempt towards achieving a completely curative resection, it is inevitable that a greater number of ‘incomplete’ R2 resections is performed [32]. …”

Performance of Integrated FDG-PET/Contrast-enhanced CT in the Diagnosis of Recurrent Pancreatic Cancer: Comparison with Integrated FDG-PET/Non-contrast-enhanced CT and Enhanced CT

“…The dismal prognosis is related to the aggressive biology of this tumor entity, and the presence of undetected extrapancreatic tumor spread at the time of surgery. An early diagnosis and accurate postoperative staging is crucial for prescribing an optimal individualized chemotherapy regimen and thus elevating the survival rate [4,5]. In view of the high probability of relapse, clinical follow-up includes close surveillance, periodic evaluation of carbohydrate antigen 19-9 (CA19-9) levels, and the use of several imaging modalities such as ultrasound sonography, computed tomography (CT), and magnetic resonance imaging (MRI).…”